Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERES: CBD+THC for Refractory Seizures
NCT03808935Phase 3Terminated
- Sponsor
- Ontario Brain Institute
- Start
- Jan 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol and dronabinol in epilepsy, sponsored by Ontario Brain Institute. Primary endpoint: Frequency of convulsive seizures. Started Jan 2019; status: terminated.
02
Drugs
cannabidioldronabinol
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03808935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03808935.